Congenital heart diseaseCohort study
Advanced heart failure in adult congenital heart disease: the role of renal dysfunction in management and outcomes
- Retrospective cohort study
- single-centre
Authors' conclusion
Adult patients with CHD admitted with acute HF are a high-risk cohort. CKD is common and triples the risk of death/transplantation/VAD.
Study context
- Population
- Adults with congenital heart disease admitted with acute heart failure (HF), 2010–2021
- Participants
- 176 HF admissions
- Outcome
- Death or transplantation/VAD post-discharge; association with renal dysfunction (CKD: eGFR <60 mL/min/1.73 m²)
Main finding
As reported in the abstract
Transplant- or VAD-free survival post-discharge
1-year transplant/ventricular assist device (VAD)-free survival
75.4% (95% CI 69.2-82.3%)
5-year transplant/VAD-free survival
43.3% (95% CI 36-52%)
Observational data: associations, not effects.
Further findings
In-hospital mortality
- In-hospital mortality rate
- 4.5%
Inpatient management
- Median length of IV diuretic therapy
- 7 (4-12) days
- Maximum diuretic dose
- 120 (80-160) mg furosemide equivalents/day
- Inotropic support required
- 15.3%
- Chronic kidney disease (CKD) present
- one-quarter of patients
Original publication
Advanced heart failure in adult congenital heart disease: the role of renal dysfunction in management and outcomes. Eur J Prev Cardiol. Published 28 March 2023. doi:10.1093/eurjpc/zwad094
Summarised from the published abstract; every number is checked against it